Takeda Pharmaceutical Company Limited (4502.T) JPX

4,764.00

-86(-1.77%)

Updated at June 03 03:21PM

Currency In JPY

Key Executives

Name	Title	Pay	Year Born
Christophe Weber	President, Chief Executive Officer & Representative Director	830M	1966
Milano Furuta	Chief Financial Officer & Director	232M	1978
Andrew S. Plump	President of Research & Development and Representative Director	574M	1965
Michael Fox	Chief Operating Officer	0	N/A
Seigo Izumo	Chair of Management Board	0	N/A
Christopher David O'Reilly	Global Head of Investor Relations & Global Finance	0	N/A
Norimasa Takeda	Chief Accounting Officer & Corporate Controller	0	N/A
Gabriele Ricci	Chief Data & Technology Officer	0	1978
Haruhiko Hirate	Member of Management Board	0	1957
Salvatore Alesci	Member of Management Board and Head of R&D Global Science & Biomedical Policy	0	1975
Iwaaki Taniguchi	Senior Vice President of Corporate Finance & Controlling Department	0	N/A

Name

Title

Pay

Year Born

Christophe Weber

President, Chief Executive Officer & Representative Director

830M

1966

Milano Furuta

Chief Financial Officer & Director

232M

1978

Andrew S. Plump

President of Research & Development and Representative Director

574M

1965

Michael Fox

Chief Operating Officer

N/A

Seigo Izumo

Chair of Management Board

N/A

Christopher David O'Reilly

Global Head of Investor Relations & Global Finance

N/A

Norimasa Takeda

Chief Accounting Officer & Corporate Controller

N/A

Gabriele Ricci

Chief Data & Technology Officer

1978

Haruhiko Hirate

Member of Management Board

1957

Salvatore Alesci

Member of Management Board and Head of R&D Global Science & Biomedical Policy

1975

Iwaaki Taniguchi

Senior Vice President of Corporate Finance & Controlling Department

N/A

Description

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.